Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
David B Price, William Henley, José Eduardo Delfini Cançado, Leonardo M Fabbri, Huib A M Kerstjens, Alberto Papi, Nicolas Roche, Elif Şen, Dave Singh, Claus F Vogelmeier, Sara Barille, Elena Nudo, Victoria Carter, Derek Skinner, Rebecca Vella & George Georges. (2022) Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 355-370.
Read now
Read now
Rezwanul Hasan Rana, Khorshed Alam, Syed Afroz Keramat & Jeff Gow. (2022) Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review. Expert Review of Respiratory Medicine 16:10, pages 1067-1084.
Read now
Read now
Jean Bourbeau, Mona Bafadhel, Neil C Barnes, Chris Compton, Valentina Di Boscio, David A Lipson, Paul W Jones, Neil Martin, Gudrun Weiss & David M G Halpin. (2021) Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 499-517.
Read now
Read now
Paola Rogliani & Luigino Calzetta. (2021) Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. Expert Opinion on Pharmacotherapy 22:7, pages 943-945.
Read now
Read now
Beatrice Ludovica Ritondo, Ermanno Puxeddu, Luigino Calzetta, Mario Cazzola & Paola Rogliani. (2021) Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opinion on Pharmacotherapy 22:5, pages 611-620.
Read now
Read now
Masakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, Osamu Hataji, Gary T Ferguson, Klaus F Rabe, Nobuya Hayashi, Hiroshi Okada, Mami Takikawa, Eric Bourne, Shaila Ballal, Kiernan DeAngelis, Magnus Aurivillius, Colin Reisner & Paul Dorinsky. (2019) Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2993-3002.
Read now
Read now
Sergey Avdeev, Zaurbek Aisanov, Vladimir Arkhipov, Andrey Belevskiy, Igor Leshchenko, Svetlana Ovcharenko, Evgeny Shmelev & Marc Miravitlles. (2019) Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1267-1280.
Read now
Read now
Courtney Crim, Michael L Watkins, Eric D Bateman, Gregory J Feldman, Isabelle Schenkenberger, Edward M Kerwin, Catriona Crawford, Krishna Pudi, Shuyen Ho, Charlotte Baidoo & Ramiro Castro-Santamaria. (2019) Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 615-629.
Read now
Read now
Articles from other publishers (14)
Paola Rogliani, Josuel Ora, Francesco Cavalli, Mario Cazzola & Luigino Calzetta. (2022) Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score. Journal of Clinical Medicine 11:15, pages 4491.
Crossref
Crossref
Chih-Cheng Lai, Chao-Hsien Chen, Kuang-Hung Chen, Cheng-Yi Wang, Tsan-Ming Huang, Ya-Hui Wang & Hao-Chien Wang. (2022) The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Life 12:2, pages 173.
Crossref
Crossref
Fulvio Braido, Angelo G. Corsico, Davide Paleari, Alessio Piraino, Luca Cavalieri & Nicola Scichilone. (2022) Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution. Therapeutic Advances in Respiratory Disease 16, pages 175346662110660.
Crossref
Crossref
Svetlana I. Ovcharenko & Andrey S. Belevskiy. (2021) Benefit/risk ratio profile of single inhaler triple therapy for сhronic obstructive pulmonary disease patients. PULMONOLOGIYA 31:5, pages 645-652.
Crossref
Crossref
Sunny Jabbal, Chris RuiWen Kuo & Brian Lipworth. (2020) Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. Clinical & Experimental Allergy 50:10, pages 1140-1147.
Crossref
Crossref
I. N. Trofimenko & B. A. Chernyak. (2020) Extrafine combination beclomethasone dipropionate/ formoterol therapy in obstructive lung diseases. Meditsinskiy sovet = Medical Council:11, pages 108-115.
Crossref
Crossref
Brian Lipworth, Rory Chan, Samuel Lipworth & Chris RuiWen Kuo. (2020) Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. The Journal of Allergy and Clinical Immunology: In Practice 8:6, pages 1798-1801.
Crossref
Crossref
Brian Lipworth, Rory Chan & Chris RuiWen Kuo. (2020) Pneumonia Due to Inhaled Corticosteroids in COPD. Chest 157:6, pages 1683-1684.
Crossref
Crossref
Brian Lipworth, Rory Chan & Chris RuiWen Kuo. (2020) Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers. Chest 157:4, pages 1045.
Crossref
Crossref
Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, Roopa Trivedi, Earl St Rose, Shaila Ballal, Julie McLaren, Patrick Darken, Colin Reisner & Paul Dorinsky. (2019) A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine 158, pages 59-66.
Crossref
Crossref
S. N. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, I. V. Leshchenko, S. I. Ovcharenko, E. I. Shmelev & M. Miravitls. (2019) Withdrawal of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Russian Pulmonology 29:3, pages 334-345.
Crossref
Crossref
Brian Lipworth & Chris RuiWen Kuo. (2019) Real-World Studies in Infrequently Exacerbating Patients With COPD. Chest 156:2, pages 415-416.
Crossref
Crossref
Luigino Calzetta, Mario Cazzola, Maria Gabriella Matera & Paola Rogliani. (2019) Adding a LAMA to ICS/LABA Therapy. Chest 155:4, pages 758-770.
Crossref
Crossref
I. V. Leshchenko. (2018) Possibilities and limitations of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease. Russian Pulmonology 28:5, pages 602-612.
Crossref
Crossref